Trial Shows Promise For Arthritis Drug

[Guest guest]

Trial Shows Promise For Arthritis Drug

ScienceDaily (June 27, 2009) — A clinical trial of masitinib, a drug

in development for the treatment of rheumatoid arthritis, has shown it

to be well tolerated and effective. Researchers writing in BioMed

Central's open access journal Arthritis Research and Therapy have

shown that treatment with masitinib significantly reduced the severity

of active arthritis.

http://www.sciencedaily.com/releases/2009/06/090626190933.htm

[Guest guest]

Now I wonder what its worst side effects are that are not listed on the site.

Thanks and keep it coming.

We are encouraged from this study that masitinib not only appears to be

effective, but that within the first 3 months of treatment the worst of its

side-effects were over, possibly making it suitable for long-term treatment

regimens

 

Arshad

From: marysue <marysue@...>

Subject: [ ] Trial Shows Promise For Arthritis Drug

" RA " < >

Date: Sunday, June 28, 2009, 9:23 AM

Trial Shows Promise For Arthritis Drug

ScienceDaily (June 27, 2009) — A clinical trial of masitinib, a drug 

in development for the treatment of rheumatoid arthritis, has shown it 

to be well tolerated and effective. Researchers writing in BioMed 

Central's open access journal Arthritis Research and Therapy have 

shown that treatment with masitinib significantly reduced the severity 

of active arthritis.

http://www.sciencedaily.com/releases/2009/06/090626190933.htm

------------------------------------

[Guest guest]

 

Results of Masitinib as reported by Dr Google

Improvement was observed in all efficacy endpoints, including ACR20/50/70 scores

of 54%, 26% and 8%, respectively, and a reduction in CRP level by greater than

50% for approximately half the population. This improvement was sustainable

throughout an extension phase (>84 weeks) and was also independent of initial

DMARD resistance (anti-tumour necrosis factor-alpha and/or methotrexate). A

relatively high patient withdrawal rate (37%) required the use of last

observation carried forward (LOCF) data imputation. Incidence of adverse events

was high (95%), although the majority were of mild or moderate severity with a

considerable decline in frequency observed after 12 weeks of treatment. Two

nonfatal serious adverse events were reported. Dose-response analyses

tentatively indicate that an initial dosing level of 6.0 mg/kg per day

administered orally in two daily intakes is the most appropriate, based upon

potency and tolerability trends.

 

Arshad

From: marysue <marysue@...>

Subject: [ ] Trial Shows Promise For Arthritis Drug

" RA " < >

Date: Sunday, June 28, 2009, 9:23 AM

Trial Shows Promise For Arthritis Drug

ScienceDaily (June 27, 2009) — A clinical trial of masitinib, a drug 

in development for the treatment of rheumatoid arthritis, has shown it 

to be well tolerated and effective. Researchers writing in BioMed 

Central's open access journal Arthritis Research and Therapy have 

shown that treatment with masitinib significantly reduced the severity 

of active arthritis.

http://www.sciencedaily.com/releases/2009/06/090626190933.htm

------------------------------------